Medicenna Therapeutics (TSE:MDNA) Hits New 52-Week Low – Here’s What Happened

Shares of Medicenna Therapeutics Corp. (TSE:MDNA) reached a new 52-week low on Monday . The company traded as low as C$0.38 and last traded at C$0.40, with a volume of 72738 shares. The stock had previously closed at C$0.41.

Medicenna Therapeutics Trading Down 2.5%

The company has a debt-to-equity ratio of 4.79, a current ratio of 1.52 and a quick ratio of 4.65. The firm has a fifty day simple moving average of C$0.50 and a 200-day simple moving average of C$0.73. The firm has a market cap of C$32.95 million, a P/E ratio of -2.63 and a beta of 2.89.

Medicenna Therapeutics (TSE:MDNA) last released its quarterly earnings data on Thursday, June 25th. The company reported C($0.05) EPS for the quarter. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 219.30%. On average, equities research analysts expect that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current year.

About Medicenna Therapeutics

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.